Antitrust Antitrust

Pfizer, Flynn Pharma see UK dominance-abuse fines reimposed for ‘excessive’ drug pricing

By Simon Zekaria
  • 21 Jul 2022 13:54
  • 21 Jul 2022 14:33
Pfizer and Flynn Pharma today were fined a combined 70 million pounds ($83 million) by the UK competition regulator for abusing a dominant position over epilepsy-drug pricing, four years after the watchdog's previous landmark antitrust sanction against the companies was quashed in court.
The bulk of the Competition and Markets

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Simon Zekaria

Senior Correspondent

Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.

Discover MLex

Stay on top of global regulatory developments

Latest News